| Title: | Renin-angiotensin system inhibitors and mortality among diabetic patients with STEMI undergoing mechanical reperfusion during the COVID-19 pandemic |
|---|
| Authors: | ID De Luca, Giuseppe (Author)
ID Nardin, Matteo (Author)
ID Algowhary, Magdy (Author)
ID Uguz, Berat (Author)
ID Oliveira, Dinaldo C. (Author)
ID Ganyukov, Vladimir (Author)
ID Zimbakov, Zan (Author)
ID Čerček, Miha (Author)
ID Okkels Jensen, Lisette (Author)
ID Loh, Poay Huan (Author), et al. |
|---|
| Files: |  PDF - Presentation file, download (1,41 MB)
MD5: 60CAA2E7EB60749EAB743BFC5EA07C2A
 URL - Source URL, visit https://www.sciencedirect.com/science/article/pii/S2666970621000226
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  UKC LJ - Ljubljana University Medical Centre
|
|---|
| Abstract: | Background: During the coronavirus disease 2019 (COVID-19) pandemic, concerns have been arisen on the use of renin-angiotensin system inhibitors (RASI) due to the potentially increased expression of Angiotensinconverting-enzyme (ACE)2 and patient’s susceptibility to SARS-CoV2 infection. Diabetes mellitus have been recognized favoring the coronavirus infection with consequent increase mortality in COVID-19. No data have been so far reported in diabetic patients suffering from ST-elevation myocardial infarction (STEMI), a very high-risk population deserving of RASI treatment. Methods: The ISACS-STEMI COVID-19 registry retrospectively assessed STEMI patients treated with primary percutaneous coronary intervention (PPCI) in March/June 2019 and 2020 in 109 European high-volume primary PCI centers. This subanalysis assessed the prognostic impact of chronic RASI therapy at admission on mortality and SARS-CoV2 infection among diabetic patients. Results: Our population is represented by 3812 diabetic STEMI patients undergoing mechanical reperfusion, 2038 in 2019 and 1774 in 2020. Among 3761 patients with available data on chronic RASI therapy, between those ones with and without treatment there were several differences in baseline characteristics, (similar in both periods) but no difference in the prevalence of SARS-CoV2 infection (1.6% vs 1.3%, respectively, p = 0.786). Considering in-hospital medication, RASI therapy was overall associated with a significantly lower in-hospital mortality (3.3% vs 15.8%, p < 0.0001), consistently both in 2019 and in 2010. Conclusions: This is first study to investigate the impact of RASI therapy on prognosis and SARS-CoV2 infection of diabetic patients experiencing STEMI and undergoing PPCI during the COVID-19 pandemic. Both preadmission chronic RASI therapy and in-hospital RASI did not negatively affected patients’ survival during the hospitalization, neither increased the risk of SARS-CoV2 infection. |
|---|
| Keywords: | RAAS inhiibitors, mortality, diabetes, STEMI, COVID-19 |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Year of publishing: | 2021 |
|---|
| Number of pages: | 9 str. |
|---|
| Numbering: | Vol. 4, [article no.] 100022 |
|---|
| PID: | 20.500.12556/DiRROS-28588  |
|---|
| UDC: | 616.12:616.379-008.64 |
|---|
| ISSN on article: | 2666-9706 |
|---|
| DOI: | 10.1016/j.deman.2021.100022 |
|---|
| COBISS.SI-ID: | 272812035 |
|---|
| Note: | Nasl. z nasl. zaslona;
Opis vira z dne 24. 3. 2026;
|
|---|
| Publication date in DiRROS: | 24.03.2026 |
|---|
| Views: | 37 |
|---|
| Downloads: | 10 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
